Drug-eluting stents

Optimal Stent Design for High Bleeding Risk Patients: Evidence From a Network Meta-Analysis

03/01/2021

Giovanni M. Vescovo , MD;

Juan Guido Chiabrando , MD;

Marco Lombardi , MD;

Massimiliano Camilli , MD;

Marco Giuseppe Del Buono , MD;

Krishna Ravindra , MD;

Giuseppe G.L. Biondi-Zoccai , MD, PhD;

Rocco Antonio Montone , MD;

Giampaolo Niccoli , MD, PhD;

Polymer-free (PF) drug-eluting stent (DES) devices have a proven benefit over bare-metal stent (BMS) devices in previous trials. It is unknown, however, whether polymer-based (PB)-DES devices are as safe as PF-DES devices.

Polymer-free (PF) drug-eluting...

03/01/2021

Journal of Invasive Cardiology

Calcium Corner

Three-Year Data From BIOFLOW V: The Orsiro vs the Xience Drug-Eluting Stents

05/11/2020

David E. Kandzari , MD;

The 3-year data have shown us a continued, highly significant statistically but also very clinically meaningful difference in the outcomes of target vessel-related myocardial infarction, target lesion revascularization, and the composite of...

The 3-year data have shown us a...

05/11/2020

Cath Lab Digest

Plaque Sealing With Drug-Eluting Stents Versus Medical Therapy for Treating Intermediate Non-Obstructive Saphenous Vein Graft Lesions: A Pooled Analysis of the VELETI and VELETI II Trials

10/29/2019

Sanjit S. Jolly , MD, MSc, FRCP;

Vladimír Dzavík , MD, FRCPC, FSCAI;

Josep Rodés-Cabau , MD, PhD;

Frédéric Maes , MD, PhD;

John Cairns , MD;

Robert De Larochellière , MD;

Melanie Côté , MD, MSc;

The presence of intermediate “non-obstructive” saphenous vein graft lesions is a strong predictor of cardiac events. Our study aims to assess the efficacy of sealing these saphenous vein graft lesions with drug-eluting stent implantation for...

The presence of intermediate...

10/29/2019

Journal of Invasive Cardiology

Resolute Onyx 2.0: A New Tool for Small Vessel Coronary Artery Disease

09/05/2019

Jeffrey B. Ai , EMT;

Zhaowei Ai , MD, PhD, FACC;

It is estimated that 65% of extra-small vessels are located in critical locations of the heart.8

It is estimated that 65% of...

09/05/2019

Cath Lab Digest

Long-Term Clinical Safety and Efficacy: The Orsiro Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stent

06/07/2019

David E. Kandzari , MD;

Can you describe the Orsiro stent?

Can you describe the Orsiro...

06/07/2019

Cath Lab Digest

The Incidence of Non-Cardiac Surgery in Patients Treated With Drug-Eluting Stents According to Age

01/30/2019

Oh-Hyun Lee , MD;

Jung-Sun Kim , MD;

Sung-Jin Hong , MD;

Young-Guk Ko , MD;

Chul-Min Ahn , MD;

Donghoon Choi , MD, PhD;

Yangsoo Jang , MD, PhD;

Myeong-Ki Hong , MD;

Byeong-Keuk Kim , MD, PhD;

We evaluated the incidence and timing of non-cardiac surgery after drug-eluting stent implantation according to patient age.

We evaluated the incidence and...

01/30/2019

Journal of Invasive Cardiology

News

News: Onyx 1-Month OCT Study Provides Potential Insights on DAPT Duration in Complex Patients Following Stent Implantation

05/28/2018

Investigators unveiled clinical data from the independently run Onyx 1-Month OCT Study showing strong early vessel healing in a patient population with a high percentage of patients with complex coronary artery disease who were implanted with...

Investigators unveiled clinical...

05/28/2018

Cath Lab Digest

News

News: Xience Sierra, Newest Generation of Xience Drug-Eluting Stents, Receives U.S. Food and Drug Administration (FDA) Approval

05/28/2018

Design innovations in Xience Sierra include a thinner profile, increased flexibility, longer lengths, and small diameters.

Design innovations in Xience...

05/28/2018

Cath Lab Digest

"Candy Cane" Guide Catheter Extension for Stent Delivery

07/30/2015

Theodoros I. Repanas , MD;

Emmanouil S. Brilakis , MD, PhD, FACC, FAHA, FESC, FSCAI;

Georgios Christopoulos , MD;

Stent delivery to a native coronary artery lesion located proximal to the anastomosis of a bypass graft can be challenging due to severe tortuosity. Guide catheter extensions such as the GuideLiner can facilitate equipment delivery, as...

Stent delivery to a native...

07/30/2015

Journal of Invasive Cardiology

Original Contribution

Biolimus-A9 Eluting Stent Implantion for Unprotected Left Main Coronary Artery Stenosis: 9-Month Strut Coverage as Assessed by Optical Coherence Tomography

02/01/2015

Gianni Dall'Ara , MD;

Nevio Taglieri , MD;

Claudio Rapezzi , MD;

Antonio Marzocchi , MD;

Tullio Palmerini , MD;

Francesco Saia , MD, PhD;

Gabriele Ghetti , MD;

Pamela Gallo , MD;

Carolina Moretti , MD;

Cinzia Marrozzini , MD;

Incomplete stent strut coverage is a risk factor for late stent thrombosis. This study evaluates strut coverage after biolimus-A9 eluting stent (BES) implantation for unprotected left main artery (ULMA) stenosis during follow-up and identify...

Incomplete stent strut coverage...

02/01/2015

Journal of Invasive Cardiology